Gilead Sciences Inc.
Gilead Sciences Updates Corporate Governance
Summary
On July 30, 2025, Gilead Sciences, Inc. updated its bylaws to revise procedural and disclosure requirements for director nominations, enhance disclosure standards, and modernize governance practices. The amendments, effective as of July 30, 2025, include changes to the nomination process, clarification of the white proxy card's exclusive use by the Company, updates to reflect recent Delaware law amendments, and administrative updates.
Profitelligence Alerts
Get alerts for GILD
Be first to know when Gilead Sciences Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Official SEC Documents
Advertisement